With the intent to replicate the benefit of pyrotinib in the early BC setting, the PHEDRA trial is a randomized controlled study recruiting patients with high-risk HER2+ BC, a tumor size ≥ 2 cm, and LN+. Here, ERBB2 is linked to neoplasm.